IMVT Company Profile and Key Details

Immunovant, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.94. This means the shares are trading above this model’s fair value.

Immunovant, Inc. generated EPS of -$2.68 over the past year. Five-year average earnings growth is -12.18%. Wall Street analysts project EPS growth of 4.39% annually over the next five years. The latest quarter delivered EPS of -$0.75. The next quarter is forecast at -$0.61. Next year's EPS is expected at $0.68. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 7 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $62.00 to $16.00. The high target offers 57.96% upside. The low target suggests -59.24% downside. The mean target is $38.73. This offers -1.32% upside. Immunovant, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by 19.26%. The prior quarter beat by 21.67%. Over the last six quarters, Apple has recorded several small beats. These include -10.27% in May 29, 2025.

Immunovant, Inc. has 174.32 million shares outstanding. The public float is 66.98 million shares, elevated short interest at 29.06% of float. This equals 16.43 million shares. The short ratio is 12.77 days. Institutional investors hold 122.93% of the float. Insiders own 56.06%. Roivant Sciences Ltd. holds 113.32 million shares, Salzmann Peter has 1.18 million shares and Butchko Julia G. has 440.96 thousand shares. Over the past six months, insider transactions show net selling. They sold 316.09 thousand shares across 27 transactions.

Short-term trend indicators are bearishly aligned (SMA20 3.98%, SMA50 4.25%, SMA200 37.68%). The stock’s 14-day RSI is 58.08 (neutral), while the ATR of 1.27 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.29% below its high and over 115.49% above its low. Average 10-day trading volume of 1.15 million shares is in line with the 3-month average of 1.24 million, indicating normal recent market interest.

Immunovant, Inc. (NASDAQ:IMVT) closed at $39.25 USD, gaining $0.13 (0.33%) from the previous close of $39.12. The stock is currently mid-range between its 52-week high and low $14.58 and $45.42. With a market capitalization of about $8.10 billion, Immunovant, Inc. is classified as a mid-cap and shows market-like volatility (beta ~0.81). Key stats such as the average daily volume over the past year has been around 1.26 million shares, volume is running light vs its 52-week average. Headquartered in Durham, NY, Immunovant, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Eric Venker, the company employs approximately 315 people and listed since June 21, 2019. Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions.

Immunovant, Inc. trades at a P/E ratio of -14.0, slightly below the S&P 500 average, with a price-to-sales ratio of 1148.48 and a price-to-book ratio of 11.03 reflecting a rich premium to book value. The P/FCF stands at -19.67, also below market averages. Compared to sector medians, Immunovant, Inc. P/S is trading rich, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.

Immunovant, Inc. (NASDAQ:IMVT) shares are flat 2.83% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Immunovant, Inc. trading at a premium to the broader market with a P/E of -14.0. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $35.38, suggesting -9.86% downside. Our AI forecast model points to short-term weakness (-14.68% over two weeks), a medium-term rise (68.76% over three months), and a longer-term loss (-4.59% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Immunovant, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -14.68%, with price expected at $33.49 by September 17, 2026, within a range of $31.59 to $35.67 3-Month Outlook: Projected rise of 68.76%, reaching $66.24 by December 02, 2026, with a range of $65.60 to $66.94. 1-Year Outlook: Projected loss of -4.59%, with price at $37.45 by September 03, 2027, within a range of $34.10 to $40.42.